1. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study;Lantuejoul;Lung Cancer,2020
2. IASLC Pathology Committee, Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study;Mino-Kenudson;Lung Cancer,2022
3. L.M. Sholl, F.R. Hirsch, D. Hwang, J. Botling, F. Lopez-Rios, L. Bubendorf, M. Mino-Kenudson, A.C. Roden, M.B. Beasley, A. Borczuk, E. Brambilla, G. Chen, T.-Y. Chou, J.-H. Chung, W.A. Cooper, S. Dacic, S. Lantuejoul, D. Jain, D. Lin, Y. Minami, A. Moreira, A.G. Nicholson, M. Noguchi, M. Papotti, G. Pelosi, C. Poleri, N. Rekhtman, M.-S. Tsao, E. Thunnissen, W. Travis, Y. Yatabe, A. Yoshida, J.B. Daigneault, A. Zehir, S. Peters, I.I. Wistuba, K.M. Kerr, J.W. Longshore, The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 15 (2020) 1409–1424. https://doi.org/10.1016/j.jtho.2020.05.019.
4. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study;Ricciuti;Lung Cancer,2022
5. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma;Skoulidis;Cancer Discov.,2018